DLA Piper Litigator Named Pfizer GC
The lead lawyer defending Pfizer Inc. in litigation over two of its painkillers will become the company’s general counsel.
Amy Schulman will take the place of Allen Waxman, said to have left the company for personal reasons. Schulman is a partner at DLA Piper, where she earned $5.75 million last year, the Wall Street Journal reports. Pfizer did not disclose how much it will pay her in the new position.
Schulman represented Pfizer in litigation claiming Celebrex and Bextra caused heart attacks and strokes. The Wall Street Journal reported earlier (sub. req.) this month that Pfizer reached tentative settlements with three law firms representing more than 200 out of thousands of plaintiffs. More deals may be in the works, according to the story.
The article says Schulman has “made a name for herself in litigation circles as an adept strategist and manager of large legal teams.” She also spearheaded a number of DLA Piper’s strategic initiatives in areas including client service, diversity and mentoring, according to a press release.
